AAPL   322.09 (+0.07%)
MSFT   183.05 (+0.12%)
FB   230.17 (-0.75%)
AMZN   2,468.95 (-0.08%)
NVDA   350.55 (-0.48%)
BABA   209.85 (+1.59%)
GE   6.94 (+2.66%)
TSLA   899.42 (+0.15%)
ACB   14.13 (+0.21%)
F   5.96 (+1.53%)
GILD   73.95 (-1.61%)
DIS   118.86 (+0.08%)
BAC   25.03 (+1.71%)
AAPL   322.09 (+0.07%)
MSFT   183.05 (+0.12%)
FB   230.17 (-0.75%)
AMZN   2,468.95 (-0.08%)
NVDA   350.55 (-0.48%)
BABA   209.85 (+1.59%)
GE   6.94 (+2.66%)
TSLA   899.42 (+0.15%)
ACB   14.13 (+0.21%)
F   5.96 (+1.53%)
GILD   73.95 (-1.61%)
DIS   118.86 (+0.08%)
BAC   25.03 (+1.71%)
AAPL   322.09 (+0.07%)
MSFT   183.05 (+0.12%)
FB   230.17 (-0.75%)
AMZN   2,468.95 (-0.08%)
NVDA   350.55 (-0.48%)
BABA   209.85 (+1.59%)
GE   6.94 (+2.66%)
TSLA   899.42 (+0.15%)
ACB   14.13 (+0.21%)
F   5.96 (+1.53%)
GILD   73.95 (-1.61%)
DIS   118.86 (+0.08%)
BAC   25.03 (+1.71%)
AAPL   322.09 (+0.07%)
MSFT   183.05 (+0.12%)
FB   230.17 (-0.75%)
AMZN   2,468.95 (-0.08%)
NVDA   350.55 (-0.48%)
BABA   209.85 (+1.59%)
GE   6.94 (+2.66%)
TSLA   899.42 (+0.15%)
ACB   14.13 (+0.21%)
F   5.96 (+1.53%)
GILD   73.95 (-1.61%)
DIS   118.86 (+0.08%)
BAC   25.03 (+1.71%)
Log in

NASDAQ:CATSCatasys Stock Price, Forecast & News

$20.14
+0.33 (+1.67 %)
(As of 06/2/2020 09:18 AM ET)
Add
Compare
Today's Range
$19.50
Now: $20.14
$20.45
50-Day Range
$18.86
MA: $23.94
$30.79
52-Week Range
$8.55
Now: $20.14
$32.55
Volume324,778 shs
Average Volume634,611 shs
Market Capitalization$342.18 million
P/E RatioN/A
Dividend YieldN/A
Beta2.22
Catasys, Inc. provides big data predictive analytics, artificial intelligence and telehealth, combined with human intervention services to health plans and other third party payors. It offers OnTrak solution to improve treatment outcomes and lower the utilization of medical and behavioral health plan services. The company's OnTrak solution includes medical and psychosocial interventions; and a proprietary Web based clinical information platform and database, psychosocial programs, and integrated care coaching services. Its OnTrak solution combines medical and psychosocial treatments with elements of traditional disease management, case management, and ongoing member support to help organizations treat and manage populations struggling with substance dependence, depression, and anxiety to improve their health and thereby decrease their health care costs. Catasys, Inc.'s OnTrak solution includes various components, such as identification of impactable members, member engagement, enrollment/referral, provider network, outpatient medical treatment, outpatient psychosocial treatment, care coaching, monitoring and reporting, and proprietary Web-based clinical information platform. The company was formerly known as Hythiam, Inc. and changed its name to Catasys, Inc. in March 2011. Catasys, Inc. was founded in 2000 and is based in Los Angeles, California.
Read More
Catasys logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.15 out of 5 stars


Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CATS
Previous SymbolOTCMKTS:CATS
CUSIPN/A
Phone310-444-4300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$35.10 million
Book Value($1.44) per share

Profitability

Net Income$-25,660,000.00

Miscellaneous

EmployeesN/A
Market Cap$342.18 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive CATS News and Ratings via Email

Sign-up to receive the latest news and ratings for CATS and its competitors with MarketBeat's FREE daily newsletter.

Catasys (NASDAQ:CATS) Frequently Asked Questions

How has Catasys' stock been impacted by COVID-19 (Coronavirus)?

Catasys' stock was trading at $13.17 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CATS stock has increased by 52.9% and is now trading at $20.14. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Catasys?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catasys in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Catasys.

When is Catasys' next earnings date?

Catasys is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Catasys.

How were Catasys' earnings last quarter?

Catasys, Inc. (NASDAQ:CATS) announced its earnings results on Thursday, May, 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by $0.04. The company had revenue of $12.34 million for the quarter. View Catasys' earnings history.

What guidance has Catasys issued on next quarter's earnings?

Catasys updated its FY 2020 After-Hours earnings guidance on Thursday, May, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $90 million, compared to the consensus revenue estimate of $87.31 million.

What price target have analysts set for CATS?

2 Wall Street analysts have issued 1 year price objectives for Catasys' stock. Their forecasts range from $26.00 to $35.00. On average, they anticipate Catasys' stock price to reach $30.50 in the next twelve months. This suggests a possible upside of 51.4% from the stock's current price. View analysts' price targets for Catasys.

Has Catasys been receiving favorable news coverage?

News stories about CATS stock have trended very positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Catasys earned a daily sentiment score of 3.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutCatasys.

Are investors shorting Catasys?

Catasys saw a increase in short interest in April. As of April 30th, there was short interest totaling 2,780,000 shares, an increase of 13.0% from the April 15th total of 2,460,000 shares. Based on an average daily trading volume, of 255,300 shares, the days-to-cover ratio is presently 10.9 days. Currently, 41.7% of the company's stock are short sold. View Catasys' Current Options Chain.

Who are some of Catasys' key competitors?

What other stocks do shareholders of Catasys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catasys investors own include Inseego (INSG), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), BioXcel Therapeutics (BTAI), Cisco Systems (CSCO), Alteryx (AYX), Canopy Growth (CGC), Crispr Therapeutics (CRSP) and Inovio Pharmaceuticals (INO).

Who are Catasys' key executives?

Catasys' management team includes the following people:
  • Mr. Terren S. Peizer, Founder, Chairman & CEO (Age 59)
  • Mr. Richard A. Anderson, Pres & COO (Age 50)
  • Mr. Christopher L. Shirley, Chief Financial Officer (Age 43)
  • Mr. Michael E. Green, Director of Bus. Devel.
  • Mr. Jeremiah Stone, Chief Technology Officer

What is Catasys' stock symbol?

Catasys trades on the NASDAQ under the ticker symbol "CATS."

Who are Catasys' major shareholders?

Catasys' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (2.94%), Janney Montgomery Scott LLC (1.21%), State Street Corp (0.73%), Geode Capital Management LLC (0.59%), Taylor Wealth Management Partners (0.53%) and Morgan Stanley (0.19%). Company insiders that own Catasys stock include Curtis Medeiros, David E Smith and Steve Gorlin. View institutional ownership trends for Catasys.

Which institutional investors are selling Catasys stock?

CATS stock was sold by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Janney Montgomery Scott LLC, Cetera Advisor Networks LLC, Wells Fargo & Company MN, UBS Group AG, and Deutsche Bank AG. View insider buying and selling activity for Catasys.

Which institutional investors are buying Catasys stock?

CATS stock was bought by a variety of institutional investors in the last quarter, including Taylor Wealth Management Partners, Alliancebernstein L.P., Morgan Stanley, BlackRock Inc., Nuveen Asset Management LLC, State Street Corp, Bank of New York Mellon Corp, and Baldwin Brothers Inc. MA. Company insiders that have bought Catasys stock in the last two years include Curtis Medeiros, and Steve Gorlin. View insider buying and selling activity for Catasys.

How do I buy shares of Catasys?

Shares of CATS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Catasys' stock price today?

One share of CATS stock can currently be purchased for approximately $20.14.

How big of a company is Catasys?

Catasys has a market capitalization of $342.18 million and generates $35.10 million in revenue each year. The company earns $-25,660,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis.

What is Catasys' official website?

The official website for Catasys is www.catasys.com.

How can I contact Catasys?

Catasys' mailing address is 11601 WILSHIRE BOULEVARD SUITE 1100, LOS ANGELES CA, 90025. The company can be reached via phone at 310-444-4300 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.